The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Fighting Immune Cold and Reprogramming Immunosuppressive Tumor Microenvironment with Red Blood Cell Membrane-Camouflaged Nanobullets
Abstract
Nanomedicine, acting as the magic bullet, is capable of combining immunotherapy with other treatments to reverse a cold tumor (immune depletion) into a hot tumor. However, how to comprehensively inhibit the immunosuppressive tumor microenvironment (TME) remains a major challenge for immunotherapy to achieve the maximum benefits. Thus, a strategy that can simultaneously increase the recruitment of tumor infiltrating lymphocytes (TILs) and comprehensively reprogram the immunosuppressive TME is still urgently needed. Herein, a thermal-sensitive nitric oxide (NO) donor S-nitrosothiols (SNO)-pendant copolymer (poly(acrylamide- co -acrylonitrile- co -vinylimidazole)-SNO copolymer, PAAV-SNO) with upper critical solution temperature (UCST) was synthesized and employed to fabricate an erythrocyte membrane-camouflaged nanobullet for codelivery of NIR II photothermal agent IR1061 and indoleamine 2,3-dioxygenase 1 (IDO-1) inhibitor 1-methyl-tryptophan (1-MT). This multifunctional nanobullet possessed long circulation in vivo, enhanced accumulation at the tumor site, and therapeutics-controlled release by NIR II laser, thereby it could avoid unspecific drug leakage while enhancing biosecurity. More importantly, the immunogenic cell death (ICD) induced by local hyperthermia from photothermal therapy (PTT) could be conducive for the increased recruitment of CD8+ cytotoxic T lymphocytes (CTLs) at the tumor site. Furthermore, through interfering in the IDO-1 activity by 1-MT and normalizing the tumor vessels by in situ generated NO, the immunosuppressive TME was comprehensively reprogrammed toward an immunostimulatory phenotype, achieving the excellent therapeutic efficacy against both primary breast cancer and metastases. Collectively, this multifunctional nanobullet described in this study developed an effective and promising strategy to comprehensively reprogram suppressive TME and treat “immune cold” tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nitric oxide and the immune response
Bogdan, C. (2001) · Nature Immunology · doi:10.1038/ni1001-907 · Cited by 3,447
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
Fukumura, D., Kloepper, J., Amoozgar, Z., Duda, D. G., & Jain, R. K. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.29 · Cited by 2,027
Skin blood flow in adult human thermoregulation: How it works, when it does not, and why
Charkoudian, N. (2003) · Mayo Clinic Proceedings · doi:10.4065/78.5.603 · Cited by 1,041
A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells
Barsoum, I. B., Smallwood, C. A., Siemens, D. R., & Graham, C. H. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-0992 · Cited by 767
Nitric oxide release: Part I. Macromolecular scaffolds
Riccio, D. A., & Schoenfisch, M. H. (2012) · Chemical Society Reviews · doi:10.1039/c2cs15272j · Cited by 475
Barsoum, I. B., Hamilton, T. K., Li, X., Cotechini, T., Miles, E. A., Siemens, D. R., & Graham, C. H. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-2104 · Cited by 188
PD-L1 expression is regulated by hypoxia inducible factor in clear cell renal cell carcinoma
Ruf, M., Moch, H., & Schraml, P. (2016) · International Journal of Cancer · doi:10.1002/ijc.30077 · Cited by 179
Li, J., Jiang, R., Wang, Q., Li, X., Hu, X., Yuan, Y., Lu, X., Wang, W., Huang, W., & Fan, Q. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119304 · Cited by 163
Neufeld, M. J., Harding, J. L., & Reynolds, M. M. (2015) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.5b08773 · Cited by 116
Yang, Z., Cheng, R., Zhao, C., Sun, N., Luo, H., Chen, Y., Liu, Z., Li, X., Liu, J., & Tian, Z. (2018) · Theranostics · doi:10.7150/thno.26195 · Cited by 89
Self-citation
Cited by
Phototherapy in cancer treatment: strategies and challenges
Cai, Y., Chai, T., Nguyen, W., Liu, J., Xiao, E., Ran, X., Ran, Y., Du, D., Chen, W., & Chen, X. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02140-y · Cited by 453
Recent progress in targeted delivery vectors based on biomimetic nanoparticles
Chen, L., Hong, W., Ren, W., Xu, T., Qian, Z., & He, Z. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00631-2 · Cited by 374
Li, M., Zhang, Y., Lian, L., Liu, K., Lu, M., Chen, Y., Zhang, L., Zhang, X., & Wan, P. (2022) · Advanced Functional Materials · doi:10.1002/adfm.202208141 · Cited by 329
Self-citationRecent applications of immunomodulatory biomaterials for disease immunotherapy
Dai, H., Fan, Q., & Wang, C. (2022) · Exploration · doi:10.1002/exp.20210157 · Cited by 268
Recent strategies for nano-based PTT combined with immunotherapy: from a biomaterial point of view
Huang, X., Lu, Y., Guo, M., Du, S., & Han, N. (2021) · Theranostics · doi:10.7150/thno.56482 · Cited by 265
Self-citation
Metadata
- Authors
- Yang, Z., Gao, D., Guo, X., Jin, L., Zheng, J., Wang, Y., Chen, S., Zheng, X., Zeng, L., Guo, M., Zhang, X., & Tian, Z.
- Venue
- ACS Nano
- Publisher
- American Chemical Society (ACS)
- Published
- 2020-11-09
- Volume
- 14
- Issue
- 12
- Pages
- 17442-17457
- ISSN
- 1936-0851 (ISSN-L)
- 1936-086X
- OpenAlex
- W3102549282
- Cited by
- 275
- References
- 10
- FWCI
- 13.42
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.